The DOI matches its Crossref record; 37 of the 40 references it cites were found in a registry or an index, and 3 are not checked yet.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
Open accessAbstract
BACKGROUND: The most appropriate targets for systolic blood pressure to reduce cardiovascular morbidity and mortality among persons without diabetes remain uncertain. METHODS: We randomly assigned 9361 persons with a systolic blood pressure of 130 mm Hg or higher and an increased cardiovascular risk, but without diabetes, to a systolic blood-pressure target of less than 120 mm Hg (intensive treatment) or a target of less than 140 mm Hg (standard treatment). The primary composite outcome was myocardial infarction, other acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. RESULTS: At 1 year, the mean systolic blood pressure was 121.4 mm Hg in the intensive-treatment group and 136.2 mm Hg in the standard-treatment group. The intervention was stopped early after a median follow-up of 3.26 years owing to a significantly lower rate of the primary composite outcome in the intensive-treatment group than in the standard-treatment group (1.65% per year vs. 2.19% per year; hazard ratio with intensive treatment, 0.75; 95% confidence interval [CI], 0.64 to 0.89; P<0.001). All-cause mortality was also significantly lower in the intensive-treatment group (hazard ratio, 0.73; 95% CI, 0.60 to 0.90; P=0.003). Rates of serious adverse events of hypotension, syncope, electrolyte abnormalities, and acute kidney injury or failure, but not of injurious falls, were higher in the intensive-treatment group than in the standard-treatment group. CONCLUSIONS: Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01206062.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the Systolic Blood Pressure Intervention Trial, 261 patients at high cardiovascular risk who were already using antihypertensive drugs targeting a systolic BP of 120 mmHg had an approximately twofold risk of syncope vs. the control group targeting a systolic BP of 140 mmHg.”
From 2018 ESC Guidelines for the diagnosis and management of syncope (2018) · cites this paper as [261]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results have been interpreted to be generally consistent between the two trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (38,40).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular benefit of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The primary composite outcome of MI, coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (38).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“The results of BPROAD and ESPRIT are supported by the Systolic Blood Pressure Intervention Trial (SPRINT), which demonstrated that treatment to a goal systolic blood pressure of <120 mmHg decreases cardiovascular event rates by 25% in high-risk individuals, although people with diabetes were excluded from this trial (44).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury (AKI), were more common in the intensive treatment arm”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [44]
In the citing paper
“in which there was a notable 25% relative/0.5% absolute reduced risk per year of cardiovascular morbidity and mortality with intensive (<120 mm Hg) as compared with standard (<140 mm Hg) systolic blood pressure control in patients with hypertension and high cardiovascular risk.71”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [71]
In the citing paper
“This graded approach is based on evidence from multiple meta-analyses and individual RCTs, which show a consistent and graded reduction in CVD risk in response to reductions in TC and LDL-C levels. 61-71”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
In the citing paper
“These trials are consistent in showing that the higher the initial LDL-C level, the greater the absolute reduction in risk, while the relative risk reduction remains constant at any given baseline LDL-C level.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [70]
In the citing paper
“The primary composite outcome of myocardial infarction (MI), coronary syndromes, stroke, heart failure, or death from cardiovascular causes was reduced by 25% in the intensive treatment group.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that treatment to a target systolic blood pressure of < 120 mmHg decreases cardiovascular event rates by 25% in high-risk patients, although people with diabetes were excluded from this trial (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Of note, the ACCORD BP and SPRINT trials targeted a similar systolic blood pressure < 120 mmHg, but in contrast to SPRINT, the primary composite cardiovascular end point was nonsigni fi cantly reduced in ACCORD BP.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The achieved systolic blood pressures in the trial were 121 mmHg and 136 mmHg in the intensive versus standard treatment group, respectively.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“Adverse outcomes, including hypotension, syncope, electrolyte abnormality, and acute kidney injury were more common in the intensive treatment arm; risk of adverse outcomes needs to be weighed against the cardiovascular bene fi t of more intensive blood pressure lowering.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
In the citing paper
“The results have been interpreted to be generally consistent between both trials, but ACCORD BP was viewed as underpowered due to the composite primary end point being less sensitive to blood pressure regulation (33).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [33]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Lim, S. S., Vos, T., Flaxman, A. D., Danaei, G., Shibuya, K., Adair-Rohani, H., AlMazroa, M. A., Amann, M., Anderson, H. R., Andrews, K. G., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61766-8 · Cited by 11,805
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Global burden of hypertension: analysis of worldwide data
Kearney, P. M., Whelton, M., Reynolds, K., Muntner, P., Whelton, P. K., & He, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17741-1 · Cited by 8,698
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Self-citationHeart Disease and Stroke Statistics—2014 Update
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2013) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,264
Blood pressure, stroke, and coronary heart disease
Collins, R., Peto, R., MacMahon, S., Godwin, J., Qizilbash, N., Collins, R., MacMahon, S., Hebert, P., Eberlein, K. A., Taylor, J. O., et al. (1990) · The Lancet · doi:10.1016/0140-6736(90)90944-z · Cited by 4,491
Research works printed but not linked: 3
- 10.1016/s0140-6736(05)70151-3 · DOI
- Franklin SS, 1999, Pathol Biol (Paris), 47, 594
- Nwankwo T, 2013, NCHS Data Brief, 133, 1
Cited by
Sorted by citations
Items 501–600 of 1,036
Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension
Juraschek, S. P., Hu, J., Cluett, J., Ishak, A. M., Mita, C., Lipsitz, L. A., Appel, L. J., Beckett, N. S., Coleman, R. L., Cushman, W. C., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-4298 · Cited by 98
Blood Pressure and Risk of Cardiovascular Disease in UK Biobank
Wan, E. Y. F., Fung, W. T., Schooling, C. M., Yeung, S. L. A., Kwok, M. K., Yu, E. Y. T., Wang, Y., Chan, E. W., Wong, I. C. K., & Lam, C. L. K. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16138 · Cited by 98
Isometric Exercise Training and Arterial Hypertension: An Updated Review
Edwards, J. J., Coleman, D. A., Ritti‐Dias, R. M., Farah, B. Q., Stensel, D. J., Lucas, S. J. E., Millar, P. J., Gordon, B. D., Cornelissen, V., Smart, N. A., et al. (2024) · Sports Medicine · doi:10.1007/s40279-024-02036-x · Cited by 98
Diagnosis and Treatment of Hypertension in the 2017 ACC/AHA Guidelines and in the Real World
Ioannidis, J. P. A. (2017) · JAMA · doi:10.1001/jama.2017.19672 · Cited by 97
2019 Chinese guideline for the management of hypertension in the elderly.
Hua, Q., Fan, L. H., & Li, J. (2019) · PubMed Central · doi:10.11909/j.issn.1671-5411.2019.02.001 · Cited by 97
Kim, J., Kang, D., Park, H., Kang, M., Park, T. K., Lee, J. M., Yang, J. H., Song, Y. B., Choi, J., Choi, S., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa376 · Cited by 97
Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities
Przezak, A., Bielka, W., & Pawlik, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126500 · Cited by 97
Advances in the management of chronic kidney disease
Chen, T. K., Hoenig, M. P., Nitsch, D., & Grams, M. E. (2023) · BMJ · doi:10.1136/bmj-2022-074216 · Cited by 100
Tajeu, G. S., Kent, S. T., Kronish, I. M., Huang, L., Krousel-Wood, M. A., Bress, A. P., Shimbo, D., & Muntner, P. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07720 · Cited by 97
Timeline of History of Hypertension Treatment
Saklayen, M. G., & Deshpande, N. V. (2016) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2016.00003 · Cited by 96
Webster, L., Conti-Ramsden, F. I., Seed, P. T., Webb, A. J., Nelson‐Piercy, C., & Chappell, L. C. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005526 · Cited by 96
Personalized medicine—a modern approach for the diagnosis and management of hypertension
Savoia, C., Volpe, M., Grassi, G., Borghi, C., Rosei, E. A., & Touyz, R. M. (2017) · Clinical Science · doi:10.1042/cs20160407 · Cited by 97
Future Direction for Using Artificial Intelligence to Predict and Manage Hypertension
Krittanawong, C., Bomback, A. S., Baber, U., Bangalore, S., Messerli, F. H., & Tang, W. H. W. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0875-x · Cited by 96
Resistant Hypertension: Novel Insights
Lamirault, G., Artifoni, M., Daniel, M., Barber‐Chamoux, N., & Nantes University Hospital Working Group on Hypertension (2019) · Current Hypertension Reviews · doi:10.2174/1573402115666191011111402 · Cited by 96
Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events
Juraschek, S. P., Taylor, A. A., Wright, J. T., Evans, G. W., Miller, E. R., Plante, T. B., Cushman, W. C., Gure, T. R., Haley, W. E., Moinuddin, I., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14309 · Cited by 96
Piña, I. L., Palo, K. E. D., Brown, M. T., Choudhry, N. K., Cvengros, J. A., Whalen, D., Whitsel, L. P., & Johnson, J. C. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.08.003 · Cited by 96
Gorostidi, M., Gijón‐Conde, T., Sierra, À., Rodilla, E., Rubio, E., Vinyoles, E., Oliveras, A., Santamaría, R., Segura, J., Molinero, A., et al. (2022) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2022.09.002 · Cited by 96
Guidelines for the Management of Hypertension
Chobanian, A. V. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.08.016 · Cited by 96
A Survey of Generative Adversarial Networks for Synthesizing Structured Electronic Health Records
Ghosheh, G. O., Li, J., & Zhu, T. (2024) · ACM Computing Surveys · doi:10.1145/3636424 · Cited by 95
Lee, S. E., Lee, H., Cho, H., Choe, W.-S., Kim, H., Choi, J., Jeon, E., Kim, M., Hwang, K., Chae, S. C., et al. (2017) · JACC Heart Failure · doi:10.1016/j.jchf.2017.08.015 · Cited by 95
Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable
Dreyer, N. A. (2018) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479018763591 · Cited by 95
DiPette, D. J., Skeete, J., Ridley, E., Campbell, N. R. C., López-Jaramillo, P. A., Kishore, S. P., Jaffe, M. G., Coca, A., Townsend, R. R., & Ordúñez, P. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13426 · Cited by 95
The bidirectional association between atrial fibrillation and myocardial infarction
Frederiksen, T. C., Dahm, C. C., Preis, S. R., Lin, H., Trinquart, L., Benjamin, E. J., & Kornej, J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00857-3 · Cited by 95
Screening, identifying, and treating chronic kidney disease: why, who, when, how, and what?
Farrell, D. R., & Vassalotti, J. A. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03466-5 · Cited by 95
Ahmad, A., & Oparil, S. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.08317 · Cited by 94
Nakanishi, R., Baskaran, L., Gransar, H., Budoff, M. J., Achenbach, S. S., Al-Mallah, M. H., Cademartiri, F., Callister, T. Q., Chang, H., Chinnaiyan, K. M., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09402 · Cited by 94
Upadhya, B., Pisani, B., & Kitzman, D. W. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15141 · Cited by 94
Croall, I. D., Tozer, D. J., Moynihan, B., Khan, U., O'Brien, J. T., Morris, R. G., Cambridge, V. C., Barrick, T. R., Blamire, A. M., Ford, G. A., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.5153 · Cited by 94
Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure Reduction
Zhang, W. R., Craven, T. E., Malhotra, R., Cheung, A. K., Chonchol, M., Drawz, P. E., Sarnak, M. J., Parikh, C. R., Shlipak, M. G., & Ix, J. H. (2018) · Annals of Internal Medicine · doi:10.7326/m18-1037 · Cited by 94
Productivity Burden of Hypertension in Australia
Hird, T. R., Zomer, E., Owen, A. J., Magliano, D. J., Liew, D., & Ademi, Z. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.12606 · Cited by 94
Hypertension in adults: summary of updated NICE guidance
Boffa, R. J., Constanti, M., Floyd, C. N., & Wierzbicki, A. S. (2019) · BMJ · doi:10.1136/bmj.l5310 · Cited by 94
Artificial Intelligence and Hypertension: Recent Advances and Future Outlook
Chaikijurajai, T., Laffin, L. J., & Tang, W. H. W. (2020) · American Journal of Hypertension · doi:10.1093/ajh/hpaa102 · Cited by 94
Lacunar stroke: mechanisms and therapeutic implications
Yaghi, S. R., Raz, E., Yang, D., Cutting, S., Grory, B. M., Elkind, M. S. V., & de Havenon, A. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-326308 · Cited by 94
Blood pressure targets for the treatment of people with hypertension and cardiovascular disease
Saiz, L. C., Gorricho, J., Garjón, J., Celaya, M. C., Muruzábal, L., Malón, M. D. M., Montoya, R., & López, A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010315.pub2 · Cited by 93
Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study
Grams, M. E., Yang, W. P., Rebholz, C. M., Wang, X., Porter, A. C., Inker, L. A., Horwitz, E. J., Sondheimer, J., Hamm, L. L., He, J., et al. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.01.050 · Cited by 93
Ocular blood flow as a clinical observation: Value, limitations and data analysis
Harris, A., Guidoboni, G., Siesky, B. A., Mathew, S., Vercellin, A. C. V., Rowe, L. W., & Arciero, J. C. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100841 · Cited by 93
Lehtisalo, J., Rusanen, M., Solomon, A., Antikaínen, R., Laatikainen, T. K., Peltonen, M., Strandberg, T. E., Tuomilehto, J., Soininen, H. S., Kivipelto, M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab922 · Cited by 93
Ferreira, J. P., Girerd, N., Bozec, E., Machu, J., Boivin, J., London, G. M., Zannad, F. M., & Rossignol, P. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003529 · Cited by 93
Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker
Pontillo, C., Zhang, Z., Schanstra, J. P., Jacobs, L., Zürbig, P., Thijs, L., Ramírez‐Torres, A., Heerspink, H. J. L., Lindhardt, M. K., Klein, R., et al. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.06.004 · Cited by 93
Management of Traditional Cardiovascular Risk Factors in CKD: What Are the Data?
Gregg, L. P., & Hedayati, S. S. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.12.007 · Cited by 93
Sink, K. M., Evans, G. W., Shorr, R. I., Bates, J. T., Berlowitz, D., Conroy, M. B., Felton, D. M., Gure, T., Johnson, K. C., Kitzman, D., et al. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15236 · Cited by 92
Age and Outcomes Associated with BP in Patients with Incident CKD
Kovesdy, C. P., Alrifai, A. Z. A., Gosmanova, E. O., Lü, J., Canada, R. B., Wall, B. M., Hung, A. M., Molnar, M. Z., & Kalantar‐Zadeh, K. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08660815 · Cited by 92
Attended Versus Unattended Blood Pressure Measurement in a Real Life Setting
Bauer, F., Seibert, F. S., Rohn, B., Bauer, K., Rolshoven, E., Babel, N., & Westhoff, T. H. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.10026 · Cited by 92
ACE inhibitors and ARBs: Managing potassium and renal function
Momoniat, T., Ilyas, D., & Bhandari, S. (2019) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.86a.18024 · Cited by 92
Banerjee, D., Winocour, P. H., Chowdhury, T. A., De, P., Wahba, M. M., Montero, R., Fogarty, D. G., Frankel, A., Karalliedde, J. J., Mark, P. B., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-021-02587-5 · Cited by 92
Hypertension in chronic kidney disease—treatment standard 2023
Georgianos, P. I., & Agarwal, R. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad118 · Cited by 92
Juraschek, S. P., Cortez, M. M., Flack, J. M., Ghazi, L., Kenny, R. A., Rahman, M., Spikes, T. A., Shibao, C. A., & Biaggioni, I. (2024) · Hypertension · doi:10.1161/hyp.0000000000000236 · Cited by 92
Mant, J., McManus, R. J., Roalfe, A. K., Fletcher, K., Taylor, C. J., Martin, U., Virdee, S., Greenfield, S., & Hobbs, R. F. (2016) · BMJ · doi:10.1136/bmj.i708 · Cited by 92
New Approaches to Evaluating and Monitoring Blood Pressure
Goldberg, E. M., & Levy, P. D. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0650-9 · Cited by 92
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Cushman, W. C., Whelton, P. K., Fine, L. J., Wright, J. T., Reboussin, D. M., Johnson, K., & Oparil, S. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.06722 · Cited by 91
Verdecchia, P., Reboldi, G., & Angeli, F. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.09.001 · Cited by 91
Kovell, L. C., Ahmed, H. M., Misra, S. K., Whelton, S. P., Prokopowicz, G. P., Blumenthal, R. S., & McEvoy, J. W. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002315 · Cited by 91
Shimbo, D., Bowling, C. B., Levitan, E. B., Deng, L., Sim, J. J., Huang, L., Reynolds, K., & Muntner, P. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002524 · Cited by 91
Ohman, E. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1502240 · Cited by 91
Is High Blood Pressure Self-Protection for the Brain?
Warnert, E. A. H., Rodrigues, J. C. L., Burchell, A. E., Neumann, S., Ratcliffe, L. E. K., Manghat, N. E., Harris, A. D., Adams, Z. H., Nightingale, A. K., Wise, R. G., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.309493 · Cited by 90
Hypertension in African Americans
Musemwa, N., & Gadegbeku, C. A. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0933-z · Cited by 90
Magkas, N., Tsioufis, C. P., Thomopoulos, C., Dilaveris, P., Georgiopoulos, G. A., Doumas, M. N., Papadopoulos, D. P., & Tousoulis, D. M. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13491 · Cited by 90
Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality
Thomopoulos, C., Parati, G., & Zanchetti, A. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001787 · Cited by 90
Selvaraj, S., Claggett, B. L., Böhm, M., Anker, S. D., Vaduganathan, M., Zannad, F. M., Pieske, B. M., Lam, C. S. P., Anand, I. S., Shi, V. C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.009 · Cited by 90
Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events
Hussain, A., Sun, W., Deswal, A. M., de Lemos, J. A., McEvoy, J. W., Hoogeveen, R. C., Matsushita, K., Aguilar, D. A., Bozkurt, B., Virani, S. S., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.063 · Cited by 90
Applications of artificial intelligence for hypertension management
Tsoi, K. K. F., Yiu, K. K. L., Lee, H., Cheng, H., Wang, T., Tay, J. C., Teo, B. W., Turana, Y., Soenarta, A. A., Sogunuru, G. P., et al. (2021) · Journal of Clinical Hypertension · doi:10.1111/jch.14180 · Cited by 90
ENGAGE and EMERGE: Truth and consequences?
Kuller, L. H., & López, O. L. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12286 · Cited by 90
Treatment Intensification for Hypertension in US Ambulatory Medical Care
Mu, L., & Mukamal, K. J. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.004188 · Cited by 90
Stroke Prevention Strategies in the Developing World
Kalkonde, Y. V., Alladi, S., Kaul, S., & Hachinski, V. (2018) · Stroke · doi:10.1161/strokeaha.118.017384 · Cited by 89
Challenging the definition of hypertension in pregnancy: a retrospective cohort study
Reddy, M., Rolnik, D. L., Harris, K., Li, W., Mol, B. W., Costa, F. D. S., Wallace, E. M., & Palmer, K. R. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.12.272 · Cited by 89
The Story of the Silent Killer
Kalehoff, J. P., & Oparil, S. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-01077-7 · Cited by 89
The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy
Schuett, K. A., Marx, N., & Lehrke, M. (2023) · Circulation Research · doi:10.1161/circresaha.122.321748 · Cited by 89
Ostchega, Y., Zhang, G., Kit, B. K., & Nwankwo, T. (2017) · American Journal of Hypertension · doi:10.1093/ajh/hpx101 · Cited by 89
BP Control and Long-Term Risk of ESRD and Mortality
Ku, E., Gassman, J., Appel, L. J., Smogorzewski, M., Sarnak, M. J., Glidden, D. V., Bakris, G., Gutiérrez, O. M., Hebert, L. A., Ix, J. H., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030326 · Cited by 88
Development and Validation of a Novel Cuff-Less Blood Pressure Monitoring Device
Watanabe, N., Bando, Y., Kawachi, T., Yamakita, H., Futatsuyama, K., Honda, Y., Yasui, H., Nishimura, K., Kamihara, T., Okumura, T., et al. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.07.015 · Cited by 88
Phillips, R. A., Xu, J., Peterson, L. E., Arnold, R. M., Diamond, J. A., & Schussheim, A. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.074 · Cited by 88
Khera, R., Kondamudi, N., Zhong, L., Vaduganathan, M., Parker, J., Das, S. R., Grodin, J. L., Halm, E. A., Berry, J. D., & Pandey, A. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.22190 · Cited by 88
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 89
Hypertension and Heart Failure: From Pathophysiology to Treatment
Gallo, G., & Savoia, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126661 · Cited by 88
Lauffenburger, J. C., Landon, J. E., & Fischer, M. A. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-016-3972-z · Cited by 88
Risk for hypertension crosses generations in the community: a multi-generational cohort study
Niiranen, T., McCabe, E. L., Larson, M. G., Henglin, M., Lakdawala, N. K., Vasan, R. S., & Cheng, S. C. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx134 · Cited by 88
Yates, T., Edwardson, C. L., Celis-Morales, C., Biddle, S. J. H., Bodicoat, D., Davies, M. J., Esliger, D., Henson, J., Kazi, A., Khunti, K., et al. (2020) · The Journals of Gerontology: Series A · doi:10.1093/gerona/gly252 · Cited by 87
Is early and fast blood pressure control important in hypertension management?
Volpe, M., Gallo, G., & Tocci, G. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.12.026 · Cited by 87
Prediction of cardiovascular disease among hematopoietic cell transplantation survivors
Armenian, S. H., Yang, D., Teh, J. B., Atencio, L., Gonzales, A., Wong, F. L., Leisenring, W. M., Forman, S. J., Nakamura, R., & Chow, E. J. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018019117 · Cited by 87
Colombo, E., Signore, A., Aicardi, S., Zekiy, A. O., Utyuzh, A. S., Benedicenti, S., & Amaroli, A. (2021) · Biomedicines · doi:10.3390/biomedicines9030274 · Cited by 87
How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD
Hong, K. N., Fuster, V., Rosenson, R. S., Rosendorff, C., & Bhatt, D. L. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.001 · Cited by 87
More Versus Less Intensive Blood Pressure–Lowering Strategy
Verdecchia, P., Angeli, F., Gentile, G., & Reboldi, G. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07608 · Cited by 86
Pajewski, N. M., Berlowitz, D. R., Bress, A. P., Callahan, K. E., Cheung, A. K., Fine, L. J., Gaussoin, S. A., Johnson, K., King, J. B., Kitzman, D. W., et al. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16272 · Cited by 86
Malhotra, R., Katz, R., Jotwani, V., Ambrosius, W. T., Raphael, K. L., Haley, W. E., Rastogi, A., Cheung, A. K., Freedman, B. I., Punzi, H. A., et al. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02780319 · Cited by 86
Approach and Management of Hypertension After Kidney Transplantation
Tantisattamo, E., Molnar, M. Z., Ho, B., Reddy, U. G., Dafoe, D. C., Ichii, H., Ferrey, A., Hanna, R. M., Kalantar‐Zadeh, K., & Amin, A. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00229 · Cited by 86
Pagel, P. S., Tawil, J. N., Boettcher, B. T., Izquierdo, D. A., Lazicki, T. J., Crystal, G. J., & Freed, J. K. (2020) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2020.07.016 · Cited by 86
Jiang, H., Mao, H., Lu, H., Lin, P., Garry, W., Lu, H., Yang, G., Rainer, T. H., & Chen, X. (2020) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2020.104326 · Cited by 86
Валерьевич, А. О., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Konstantinova, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6306 · Cited by 86
Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults
Saeed, A., Nambi, V., Sun, W., Virani, S. S., Taffet, G. E., Deswal, A. M., Selvin, E., Matsushita, K., Wagenknecht, L. E., Hoogeveen, R. C., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.050 · Cited by 86
Carlson, D. J., Inder, J. D., Palanisamy, S. K. A., McFarlane, J. R., Dieberg, G., & Smart, N. A. (2016) · Medicine · doi:10.1097/md.0000000000005791 · Cited by 85
Benefits and Harms of Antihypertensive Treatment in Low-Risk Patients With Mild Hypertension
Sheppard, J. P., Stevens, S., Stevens, R., Martin, U., Mant, J., Hobbs, R. F., & McManus, R. J. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.4684 · Cited by 85
Current Management of Patients With Acquired Solitary Kidney
Tantisattamo, E., Dafoe, D. C., Reddy, U. G., Ichii, H., Rhee, C. M., Streja, E., Landman, J., & Kalantar‐Zadeh, K. (2019) · Kidney International Reports · doi:10.1016/j.ekir.2019.07.001 · Cited by 85
Rosoff, D. B., Mavromatis, L. A., Bell, A. S., Wagner, J., Jung, J., Marioni, R. E., Smith, G. D., Horvath, S., & Lohoff, F. W. (2023) · Nature Aging · doi:10.1038/s43587-023-00455-5 · Cited by 89
Drug Treatment of Hypertension: Focus on Vascular Health
Cameron, A. C., Lang, N. N., & Touyz, R. M. (2016) · Drugs · doi:10.1007/s40265-016-0642-8 · Cited by 85
Hypertension in dialysis patients
Sarafidis, P. A., Persu, A., Agarwal, R., Burnier, M., de Leeuw, P. W., Ferro, C. J., Halimi, J., Heine, G. H., Jadoul, M. Y., Jarraya, F., et al. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001283 · Cited by 85
Current Concepts in the Treatment of Renovascular Hypertension
Herrmann, S. M., & Textor, S. C. (2018) · American Journal of Hypertension · doi:10.1093/ajh/hpx154 · Cited by 84
Weber, T., Lang, I. M., Zweiker, R., Horn, S., Wenzel, R. R., Watschinger, B., Slany, J., Eber, B., Roithinger, F. X., & Metzler, B. (2016) · Wiener klinische Wochenschrift · doi:10.1007/s00508-016-0998-5 · Cited by 85
Glicksberg, B. S., Johnson, K. W., & Dudley, J. T. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy114 · Cited by 84
Ritchey, M. D., Gillespie, C., Wozniak, G., Shay, C. M., Thompson‐Paul, A. M., Loustalot, F. V., & Hong, Y. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13364 · Cited by 84
Metadata
- Authors
- The SPRINT Research Group
- Affiliations
- University Hospitals Cleveland Medical Center (US)
- Corresponding author
- The SPRINT Research Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-26
- Volume
- 373
- Issue
- 22
- Pages
- 2103-2116
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4689591
- OpenAlex
- W3150595609
- Cited by
- 6,325
- References
- 38
- Citations by year
- 2026: 390 · 2025: 449 · 2024: 437 · 2023: 498 · 2022: 523 · 2021: 602 · 2020: 570 · 2019: 694 · 2018: 734 · 2017: 767 · 2016: 613 · 2015: 40
- FWCI
- 522.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000093, UL1TR000050, UL1TR001427, UL1TR000073, UL1TR001064, UL1TR001085, UL1TR000002, UL1TR000075, UL1TR000064, UL1TR000005, UL1TR000433, UL1TR000003, UL1TR000445, UL1TR000439, UL1TR000105)
- National Institute on Aging (P30AG021332)
- National Heart, Lung, and Blood Institute (HHSN268200900040C, A-HL-13-002-001, HHSN268200900049C, HHSN268200900048C, HHSN268200900047C, HHSN268200900046C)
- National Institute of General Medical Sciences (P30GM103337)
- National Center for Research Resources (UL1RR025755, UL1RR024134, UL1RR025752, UL1RR025771)
- National Center for Advancing Translational Sciences (9U54TR000017‐06)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- intensive blood pressure control, systolic blood pressure target, antihypertensive therapy, cardiovascular risk, cardiovascular events, all-cause mortality, adverse events, hypotension, acute kidney injury, non-diabetic patients
- MeSH terms
- Age Factors, Aged, Antihypertensive Agents, Blood Pressure, Cardiovascular Diseases, Cause of Death, Female, Goals, Humans, Hypertension, Male, Middle Aged, Risk Factors, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
